Abstract:Background: The 9th edition of the TNM Classification for lung cancer delineates M1c into two subcategories: M1c1 (Multiple extrathoracic lesions within a single organ system) and M1c2 (Multiple extrathoracic lesions involving multiple organ systems). Existing research indicates that patients with lung cancer in stage M1c1 exhibit superior overall survival compared to those in stage M1c2. The primary frontline therapy for patients with advanced non-small cell lung cancer (NSCLC), lacking driver gene mutations, involves the use of immune checkpoint inhibitors (ICIs) combined with chemotherapy. Nevertheless, a dearth of evidence exists regarding potential survival disparities between NSCLC patients with M1c1 and M1c2 undergoing first-line immune-chemotherapy, and reliable biomarkers for predicting treatment outcomes are elusive. Serum metabolic profiles may elucidate distinct prognostic mechanisms, necessitating the identification of divergent metabolites in M1c1 and M1c2 undergoing combination therapy. This study seeks to scrutinize survival discrepancies between various metastatic patterns (M1c1 and M1c2) and pinpoint metabolites associated with treatment outcomes in NSCLC patients undergoing first-line ICIs combined with chemotherapy. Method: In this study, 33 NSCLC patients lacking driver gene mutations diagnosed with M1c1, and 22 similarly diagnosed with M1c2 according to the 9th edition of TNM Classification, were enrolled. These patients received first-line PD-1 inhibitor plus chemotherapy. The relationship between metastatic patterns and progression-free survival (PFS) in patients undergoing combination therapy was analyzed using univariate and multivariate Cox regression models. Serum samples were obtained from all patients before treatment initiation for untargeted metabolomics analysis, aiming to identify differential metabolites. Results: In the univariate analysis of PFS, NSCLC patients in M1c1 receiving first-line PD-1 inhibitor plus chemotherapy exhibited an extended PFS (HR = 0.49, 95% CI, 0.27-0.88, p = 0.017). In multivariate PFS analyses, these M1c1 patients receiving first-line PD-1 inhibitor plus chemotherapy also demonstrated prolonged PFS (HR = 0.45, 95% CI, 0.22-0.92, p = 0.028). The serum metabolic profiles of M1c1 and M1c2 undergoing first-line PD-1 inhibitors plus chemotherapy displayed notable distinctions. In comparison to M1c1 patients, M1c2 patients exhibited alterations in various pathways pretreatment, including platelet activation, linoleic acid metabolism, and the VEGF signaling pathway. Diminished levels of lipid-associated metabolites (diacylglycerol, sphingomyelin) were correlated with adverse outcomes. Conclusion: NSCLC patients in M1c1, devoid of driver gene mutations, receiving first-line PD-1 inhibitors combined with chemotherapy, experienced superior outcomes compared to M1c2 patients. Moreover, metabolomic profiles strongly correlated with the prognosis of these patients, and M1c2 patients with unfavorable outcomes manifested distinct changes in metabolic pathways before treatment. These changes predominantly involved alterations in lipid metabolism, such as decreased diacylglycerol and sphingomyelin, which may impact tumor migration and invasion.

Prognostic Significance of Genotype and Number of Metastatic Sites in Advanced Non-Small-cell Lung Cancer.

Prognostic significance of genotype and number of metastatic sites in advanced non–small-cell lung cancer

Prognostic analysis of node status of 1 851 non-small cell lung cancer patients on the basis of the eighth TNM staging system: A cohort study

Predictive and Prognostic Significance of M Descriptors of the 8th TNM Classification for Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitors.

Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

The Number of Metastatic Lymph Nodes is More Predictive of Prognosis Than Location-Based N Stage for Nonsmall Cell Lung Cancer: a Retrospective Cohort Study.

Multivariate Survival Analysis of Patients with Stage I NSCLC

Treatment and Prognostic Analysis of 1638 Patients with Non-Small Cell Lung Cancer

Clinical Associations and Prognostic Value of Site-Specific Metastases in Non-Small Cell Lung Cancer: A Population-Based Study

Metastatic Lymph Node Station Number Predicts Survival in Small Cell Lung Cancer

P50.12 A Novel Nomogram and Risk Classification System Predicting the Survival of Patients with Extensive-stage Small Cell Lung Cancer

The prognosis and metabolite changes of NSCLC patients receiving first-line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification

Metastatic Characteristics and Prognosis of Non-Small Cell Lung Cancer

Correlation Between Characteristics of Lymph Node Metastasis and Prognosis of N1-N2 Stage Non-small Cell Lung Cancer

Comparative Analysis of Methodologies for Predicting Overall Survival in Patients with Non‐small Cell Lung Cancer Based on the Number and Rate of Resected Positive Lymph Nodes: A Study Based on the SEER Database for 2010 Through 2019

Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non–small-cell Lung Cancer

Prognostic Factors in Patients with Stage IV Non-Small Cell Lung Cancer

The Prognostic Value of Multiorgan Metastases in Patients with Non-Small Cell Lung Cancer and Its Variants: a SEER-based Study

T1aN0M0 and T1bN0M0 non-small cell lung cancer: a retrospective study of the prognosis.

Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases.